Cymbalta (duloxetin): Kontraindikationer

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Concomitant use of Cymbalta with non-selective, irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated.

Liver disease resulting in hepatic impairment.

Cymbalta should not be used in combination with fluvoxamine, ciprofloxacin or enoxacin (i.e., potent CYP1A2 inhibitors), since the combination results in elevated plasma concentrations of duloxetine.

Severe renal impairment (creatinine clearance <30 ml/min).

The initiation of treatment with Cymbalta is contraindicated in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis.

Reference

Cymbalta [Summary of Product Characteristics]. Utrecht, The Netherlands: Eli Lilly Nederland B.V.